revusiran

revusiran
Trade Name
Orphan Indication Hereditary ATTR amyloidosis
USA Market Approval USA
USA Designation Date 2015-05-18 00:00:00
Sponsor Alnylam Pharmaceuticals, Inc.;300 Third Street;Cambridge, Massachusetts, 02142
Related Access Program
Alnylam Pharmaceuticals – Amyloidosis, Hereditary, Transthyretin-Related Alnylam Pharmaceuticals – Amyloid Neuropathies, Familial Alnylam Pharmaceuticals – Familial Amyloid Polyneuropathies Alnylam Pharmaceuticals – Familial amyloid polyneuropathy